The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
The new combination therapy offers a dual mechanism of action for superior intraocular pressure control
The inspection has concluded with four observations
Positions Curium as leading manufacturer of Lu-177 isotope
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
Collaboration combines data, identity capture and Web 3.0 crypto technologies to enhance product safety, traceability, and data integrity for AI systems
The freshly infused capital will primarily be deployed towards expansion and research & development
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Subscribe To Our Newsletter & Stay Updated
